echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Diversified investments drive performance growth, and CRO leaders may usher in a harvest period

    Diversified investments drive performance growth, and CRO leaders may usher in a harvest period

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Tigermed released the 2021 annual performance forecast.
    The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
    .

    The forecast shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 2.
    625-3.
    027 billion yuan, a year-on-year increase of 50%-73%
    .
    It is estimated that the net profit after deducting non-return to the parent is 1.


    133-1.


    The financial assets invested by the company are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds .
    The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
    2-1.
    6 billion
    .

    The financial assets invested by the company are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds.

    Tigermed performance forecast table

    Source: Company Announcement

    In terms of investment, the company has established a diversified investment portfolio and actively deployed industrial chain opportunities related to its own business.
    Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
    3 billion yuan.
    For partnerships, the average capital contribution of each fund is 50 million yuan
    .
    By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies


    .


    "CRO + investment" two-wheel drive performance growth

    "CRO + investment" two-wheel drive performance growth

    Tigermed's main business focuses on clinical CRO integrated services, and drives continuous growth in performance through a model that matches investment and main business
    .
    From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.


    Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.


    Tigermed's main business focuses on clinical CRO integrated services, and drives continuous growth in performance through a model that matches investment and main business


    The direct result of Tigermed's strategic change is that the financing war in the entire innovative drug industry will heat up again.
    Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
    Strategies of pharmaceutical companies have changed
    .
    By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider


    .


    Future Investment Outlook

    Future Investment Outlook

    The company's outlook and layout for the next ten years of China's pharmaceutical investment business in the future, Tigermed is more like a platform, investment is divided into three levels, 100% holding Hangzhou Tigermed, Tigermed as GP fund and LP fund, major shareholder Individual investment, through the combination of listed company investment in relatively stable projects + fund investment plus leverage + personal venture investment, under the condition of controllable risks, maximize investment returns
    .

    The CXO industry is still in a high level of prosperity, with multiple business segments developing collaboratively.
    As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
    At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
    .
    In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas


    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.